About Cryo-Cell

• Corporate Mission
• Company Overview
• Our Leadership
• Board of Directors
• Management Team
• Medical & Scientific Advisory Board
• Our Laboratory
• International Affiliates
• Investor Relations
• Request Investor Info
• Financial Highlights
• Events & Conferences
• Contact Us
• Careers
• Company Information / Driving Instructions

Cryo-Cell International, Inc. to Present At The Rodman & Renshaw, LLC Conference

September 9, 2009

OLDSMAR, Fla. – September 9, 2009 – Cryo-Cell International, Inc. (OTC BB: CCEL) (the “Company”), one of the world’s largest and most established family cord blood banks, today announced the Company will participate at the Rodman & Renshaw 11th Annual Global Healthcare Conference to be held on September 9–11, 2009 at the New York Palace Hotel, New York, NY. Mercedes Walton, Cryo-Cell’s Chief Executive Officer is scheduled to present on Wednesday, September 9, at 2:00 p.m. Eastern Time.

The presentation will be Webcast live. Listeners can access this broadcast through Cryo-Cell`s Web site at http://cryo-cell.com/investor_relations/webcast.asp.

About Cryo-Cell International, Inc.

Based in Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. In November 2007, the Company launched C’elle (pronounced “C-L”), the world’s first-ever commercial service allowing women to cryopreserve their own menstrual stem cells. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com. For more information about C’elle visit www.celle.com.

Forward-Looking Statement

Statements wherein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the ultimate success of the Company’s pipeline of research collaborations, the actual strength of its momentum, actual future shareholder and enterprise value, the success of the Company’s global expansion initiatives, the Company’s future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.